Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:5
  • preuzimanja u poslednjih 30 dana:2

Sadržaj

članak: 7 od 96  
Back povratak na rezultate
2018, vol. 37, br. 1, str. 35-38
Pacijent sa koronarnom bolešću i hipertenzijom
aKlinika za internu medicinu Intermedica, Centar za hipertenziju, Niš
bUniverzitet u Nišu, Medicinski fakultet, Institut za prevenciju, lečenje i rehabilitaciju reumatičkih i kardioloških bolesti 'Niška Banja' - Niška Banja
cKlinički centar Srbije, Klinika za kardiologiju, Beograd
Sažetak
Smrtnost od kardiovaskularnih oboljenja , kao masovna nezarazna oboljenja, biće i u narednim godinama vodeći uzrok smrti. Mnogi faktori rizika kao što su hipertenzija, dijabetes melitus, dislipidemije i gojaznost povećavaju rizik za kardiovaskularnu smrtnost Prikaz slučaja: Pacijent sa dugogodišnjom istorijom hipertenzije, i povećanim masnoćama u krvi, tip 2 dijabetesom, gojazan javlja se na pregled sa atipičnim bolom u grudima. Pacijent ima nekontrolisan krvni pritisak i visoke vrednosti holesterola u krvi, pušač, gojazan i fizički neaktivan. Podvrgnut je kateterizaciji koronarnih arterija koja je pokazala stenozu desne koronarne arterije blizu račve sa levom koronarnom arterijom. Pacijent je nakon detaljnih analiza i pregleda otpušten na kućno lečenje uz medikamentoznu terapiju beta blokator, ACI inhibitor, statin i terapija za regulaciju šećera u krvi. Savetovana mu promena načina života i primena nefarmakoloških mera. Zaključak: Lečenje pacijenata sa koronarnom arterijskom bolešću zahteva adekvatnu kontrolu krvnog pritiska, holesterola i šećera u krvi. Mnogi vodiči relevantnih Udruženja pokušavaju u proteklim godinama da na osnovu rezultata kliničkih studija i dostupnih dokaza, preporuče optimalne ciljeve u lečenju, a sa ciljem da poprave kvalitet života i spreče komplikacije. U svakom slučaju, pacijenti sa koranarnom bolešću imaju tri opcije u lečenju: medikamentozna terapija, koronarna angioplastika i ugradnja stenta ili hirurška korekcija (by pass).
Reference
Catapano, A.L., Graham, I., de Backer, G., Wiklund, O., Chapman, M., Drexel, H., Hoes, A.W., Jennings, C.S., Landmesser, U., Pedersen, T.R., Reiner, Ž., Riccardi, G., Taskinen, M., Tokgozoglu, L. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 37(39): 2999-3058
Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T., Roccella, E.J. (2003) Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42(6): 1206-1252
CORD Study Group, Cushman, W.C., Evans, G.W., Byington, R.P., i dr. (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med, 362: 1575-1585
Emdin, C.A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., Patel, A. (2015) Blood Pressure Lowering in Type 2 Diabetes. JAMA, 313(6): 603
Ettehad, D., Emdin, C.A., Kiran, A., Anderson, S.G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., Rahimi, K. (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet, 387(10022): 957-967
Fox, K.M. (2003) EURopean trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, doubleblind,. Lancet, 362: 782-788
Julius, S., Nesbitt, S.D., Egan, B.M., Weber, M.A., Michelson, E.L., Kaciroti, N., Black, H.R., Grimm, R.H., Messerli, F.H., Oparil, S., Schork, M. (2006) Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. New England Journal of Medicine, 354(16): 1685-1697
Kotseva, K., Wood, D., de Bacquer, D., Lovic, D. (2016) EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol, Apr: 23: 636-48
Lipton, M.J., Barry, W.H., Obrez, I., Silverman, J.F., Wexler, L. (1979) Isolated Single Coronary Artery: Diagnosis, Angiographic Classification, and Clinical Significance. Radiology, 130(1): 39-47
Mancia, G., Fagard, R., Narkiewicz, K., i dr. (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 34:2159-219
Pfeffer, M.A., Braunwald, E., Moye, L.A., Basta, L., Brown, E.J., Cuddy, T.E., Davis, B.R., Geltman, E.M., Goldman, S., Flaker, G.C. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med, 327(10): 669-77
Rosendorff, C., Black, H.R., Cannon, C.P., Gersh, B.J., Gore, J., Izzo, J.L., Kaplan, N.M., o'connor C.M., o'gara P.T., Oparil, S. (2007) Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology. Circulation, 115(21): 2761-2788
Thomopoulos, C., Parati, G., Zanchetti, A. (2017) Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure. Journal of Hypertension, 35(11): 2150-2160
Thomopoulos, C., Parati, G., Zanchetti, A. (2015) Effects of blood pressure-lowering on outcome incidence in hypertension. Journal of Hypertension, str. 1
Whelton, P.K., Robert, M., i dr. (2017) ACC/AHA/ AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Journal of the American College of Cardiology, https://doi.org/10.1016/j.jacc.2017.11.006
Yusuf, S., Bosch, J., Dagenais, G. (2016) Cholesterol Lowering in Intermediate-Risk Persons Without Cardiovascular Disease. Journal of Vascular Surgery, 64(3): 827
Yusuf, S., Sleight, P., Pogue, J., i dr. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342: 145-153
 

O članku

jezik rada: engleski
vrsta rada: prikaz slučaja
DOI: 10.5937/siks1801035L
objavljen u SCIndeksu: 30.08.2018.